SG11202001762RA - Anti-egfr antibody drug conjugates (adc) and uses thereof - Google Patents

Anti-egfr antibody drug conjugates (adc) and uses thereof

Info

Publication number
SG11202001762RA
SG11202001762RA SG11202001762RA SG11202001762RA SG11202001762RA SG 11202001762R A SG11202001762R A SG 11202001762RA SG 11202001762R A SG11202001762R A SG 11202001762RA SG 11202001762R A SG11202001762R A SG 11202001762RA SG 11202001762R A SG11202001762R A SG 11202001762RA
Authority
SG
Singapore
Prior art keywords
adc
drug conjugates
antibody drug
egfr antibody
egfr
Prior art date
Application number
SG11202001762RA
Inventor
Edward Reilly
Mark Anderson
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of SG11202001762RA publication Critical patent/SG11202001762RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202001762RA 2017-09-02 2018-09-04 Anti-egfr antibody drug conjugates (adc) and uses thereof SG11202001762RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762553837P 2017-09-02 2017-09-02
PCT/US2018/049412 WO2019046859A1 (en) 2017-09-02 2018-09-04 Anti-egfr antibody drug conjugates (adc) and uses thereof

Publications (1)

Publication Number Publication Date
SG11202001762RA true SG11202001762RA (en) 2020-03-30

Family

ID=65526126

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202001762RA SG11202001762RA (en) 2017-09-02 2018-09-04 Anti-egfr antibody drug conjugates (adc) and uses thereof

Country Status (20)

Country Link
US (1) US20200188525A1 (en)
EP (1) EP3675907A4 (en)
JP (1) JP2020532523A (en)
KR (1) KR20200041998A (en)
CN (1) CN111295201A (en)
AU (1) AU2018326878A1 (en)
BR (1) BR112020004212A2 (en)
CA (1) CA3073560A1 (en)
CL (1) CL2020000508A1 (en)
CO (1) CO2020003512A2 (en)
CR (1) CR20200145A (en)
DO (1) DOP2020000045A (en)
EC (1) ECSP20020949A (en)
IL (1) IL272920A (en)
MX (1) MX2020002268A (en)
PE (1) PE20200721A1 (en)
PH (1) PH12020500417A1 (en)
RU (1) RU2020112280A (en)
SG (1) SG11202001762RA (en)
WO (1) WO2019046859A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220098242A1 (en) * 2020-02-26 2022-03-31 University Of Maryland, College Park Compositions and methods for mucosal vaccination against sars-cov-2
UY39610A (en) 2021-01-20 2022-08-31 Abbvie Inc ANTI-EGFR ANTIBODY-DRUG CONJUGATES
WO2023051814A1 (en) 2021-09-30 2023-04-06 江苏恒瑞医药股份有限公司 Pyrrolo benzodiazepine derivative, and conjugate, preparation method and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3156420T1 (en) * 2010-12-06 2019-05-31 Seattle Genetics, Inc. Humanized antibodies to liv-1 and use of same to treat cancer
JP6605444B2 (en) * 2013-03-12 2019-11-13 バイオコン・リミテッド Fusion immunoregulatory protein and production method thereof
SG10201808837RA (en) * 2014-03-21 2018-11-29 Abbvie Inc Anti-egfr antibodies and antibody drug conjugates
WO2015157595A1 (en) * 2014-04-11 2015-10-15 Medimmune, Llc Conjugated compounds comprising cysteine-engineered antibodies
US10407743B2 (en) * 2014-05-22 2019-09-10 Synthon Biopharmaceuticals B.V. Site-specific conjugation of linker drugs to antibodies and resulting ADCs
BR112018011319A2 (en) * 2015-12-04 2018-12-04 Abbvie Stemcentrx Llc new anti-claudin antibodies and methods of use

Also Published As

Publication number Publication date
DOP2020000045A (en) 2020-09-15
CA3073560A1 (en) 2019-03-07
ECSP20020949A (en) 2020-05-29
CL2020000508A1 (en) 2020-07-10
BR112020004212A2 (en) 2020-09-08
PH12020500417A1 (en) 2021-03-01
RU2020112280A (en) 2021-10-05
EP3675907A1 (en) 2020-07-08
KR20200041998A (en) 2020-04-22
CN111295201A (en) 2020-06-16
CO2020003512A2 (en) 2020-06-19
MX2020002268A (en) 2021-01-08
JP2020532523A (en) 2020-11-12
WO2019046859A1 (en) 2019-03-07
CR20200145A (en) 2020-08-03
AU2018326878A1 (en) 2020-03-19
IL272920A (en) 2020-04-30
US20200188525A1 (en) 2020-06-18
PE20200721A1 (en) 2020-07-21
EP3675907A4 (en) 2021-05-12

Similar Documents

Publication Publication Date Title
IL265309A (en) Bi specific anti-muc16-cd3 antibodies and anti-muc16 drug conjugates
IL304717A (en) Anti-cmet antibody drug conjugates and methods their use
ZA201900059B (en) Anti-b7-h3 antibodies and antibody drug conjugates
HK1257056A1 (en) Anti-dll3 antibody drug conjugates and methods of use
IL247936A0 (en) Anti-egfr antibodies and antibody drug conjugates
IL291073A (en) Anti-egfr antibody drug conjugates
IL267834A (en) Anti-ccr7 antibody drug conjugates
IL268821A (en) Hdac inhibitors-based antibody drug conjugates (adcs) and use in therapy
IL272920A (en) Anti-egfr antibody drug conjugates (adc) and uses thereof
EP3675908A4 (en) Anti-egfr antibody drug conjugates (adc) and uses thereof